Placeholder Banner

BIO Applauds USDA-FDA Agreement to Improve Coordination

January 30, 2018

Specifically, the agreement references the recently released Agricultural and Rural Prosperity Task Force’s Report and says “USDA and FDA are committed to modernizing the Coordinated Framework for the Regulation of Biotechnology and the U.S. agricultural biotechnology regulatory system to develop efficient, science-based regulatory practices for products of biotechnology by working in partnership with other federal agencies on the corresponding National Strategy for Modernizing the Regulatory Systems for Biotechnology Products.”

“BIO applauds the agreement and supports the broad recommendation to enhance coordination between the agencies governing the use of products using agricultural biotechnology,” said Dana O'Brien, BIO’s Executive Vice President for Food & Agriculture. “BIO has long supported a more harmonized Coordinated Framework for science-based regulation, especially in regard to the treatment of future products such as gene edited innovations.”

O’Brien echoed many of the proposals contained in the Task Force report and the National Strategy and said BIO looks forward to engaging with the Administration on implementation.

“We need national policies that recognize the importance of science and technology and encourage continued investment,” O’Brien said. “This agreement is another step forward towards a system that promotes ag innovation, economic growth, competitiveness and job creation in America’s thriving biotechnology sector.”

Discover More
Anthony Fauci, M.D., National Institute of Allergy and Infectious Diseases Director and Moncef Slaoui, Ph.D., U.S. Operation Warp Speed Chief Advisor…
The U.S. Department of Agriculture (USDA) released today a modernized, science-based regulatory system for plant biotechnology aimed at maintaining oversight while driving innovation. Now government and industry must do more to build an informed and…
Immunologist Michelle McMurry-Heath is Selected  for Her Global Leadership and Commitment to Innovation and Patients Former FDA Official Will…